Primary entity: Ipamorelin · Also known as: IPA; ipamorelin acetate · Class: Selective GHRP / ghrelin-receptor (GHS-R1a) agonist research peptide — not FDA-approved as consumer GH therapy · Cluster: GHRH / GHRP
Ipamorelin is a pentapeptide growth-hormone secretagogue that acts primarily at the ghrelin receptor (GHS-R1a) — the same broad receptor family as older GHRPs, with a research reputation for relatively selective GH release versus some earlier analogs. It is not a GHRH analog (that’s the CJC-1295 lineage) and not an FDA-approved chronic “peptide therapy” for fat loss, muscle, or anti-aging. Folk “CJC/Ipa” blends are covered on CJC-1295 / Ipamorelin.
Selectivity narratives in literature are not a substitute for an approved label or quality-controlled pharmacy product.
Not FDA-approved as consumer GH/anti-aging therapy. Historical clinical pharmacology exists in limited contexts — that is not an approved wellness indication.
Not covered by HHS's Oct 28, 2026 policy, which names six other peptides. Ipamorelin left the 503A Category 2 list in 2024 after a withdrawn nomination, FDA's page still lists it under 503B Category 2, and FDA staff proposed against adding it to the bulks list. It is not on the final bulks list. See the compounding status guide.
Key takeaways
- Ipamorelin → ghrelin receptor (GHS-R1a) / GHRP class — not GHRH.
- Different from CJC-1295 (and from sermorelin / tesamorelin — related but separate entities).
- Not FDA-approved stack therapy with CJC.
- Limited human pharmacology ≠ proven body-composition drug.
- No dosage chart on this site.
Questions this page answers
- What Ipamorelin is
- Aliases
- Classification
- What it is NOT
- Mechanism
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory / sport
- Why no dosages
- Related — CJC, sermorelin, stack
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who need solo Ipamorelin / GHRP literacy after seeing stack marketing.
Not for: anyone seeking a buy link, “ipa dose,” IGF DIY targets, or medical advice.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide secretagogue designed to stimulate GH release via GHS-R1a. In research discussions it is often contrasted with older GHRPs (GHRP-2, GHRP-6, hexarelin) on selectivity and side-effect reputation — contrasts that are hypothesis/literature literacy, not a guarantee for gray-market products.
Pairing with a GHRH analog (CJC / Mod GRF) is forum tradition because both can raise GH in experimental settings — marketing convenience is not combination approval.
Quick facts
| Pathway | Ghrelin receptor GHS-R1a (GHRP class) |
| Length | Pentapeptide |
| vs CJC-1295 | Different receptor (GHRH vs GHS-R1a) |
| U.S. approval (consumer therapy) | Not approved |
| Common folk pairing | CJC-1295 / Mod GRF |
Also known as
- Ipamorelin / IPA — primary names.
- Ipamorelin acetate — common salt form in commerce language.
- “CJC/Ipa,” “ipa stack” — blend shorthand — see stack page.
- Mis-tags: calling Ipamorelin a SARM; calling it CJC; equating it with MK-677 (oral ghrelin-mimetic small molecule, not this peptide).
Relative selectivity talk in papers does not create an approved consumer safety label or justify protocol pages.
How is Ipamorelin classified?
Unapproved GHRP research peptide in the ghrh-ghrp cluster. Not a SARM, not recombinant GH, not an approved IGF product.
What is Ipamorelin not?
| Ipamorelin is not… | Why that matters |
|---|---|
| CJC-1295 / Mod GRF | Different receptor pathway |
| FDA-approved GH peptide therapy | No consumer approval framing |
| A SARM | Wrong chemical/pharmacology class |
| Identical to sermorelin or tesamorelin | Related GH-axis neighborhood; different entities |
| Something we dose or source | Refusal |
How is it thought to work?
Activation of GHS-R1a stimulates pituitary GH release with a different second-messenger profile than GHRH-receptor agonism. “Selective GH release” reputations vs older GHRPs appear in research narratives; they do not automatically erase class GH-axis risks or product-quality problems.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Human clinical pharmacology | Historical IV/secretagogue work in limited contexts | [Human] Limited |
| Human outcomes (fat/muscle/anti-aging approvals) | Not established as approved indications | [None] / thin |
| Animal | GH-axis / body-composition models | [Animal] |
| Approved U.S. label (consumer ipamorelin therapy) | None | [None] |
What has been studied?
Interest centers on GH secretagogue pharmacology and biomarker dynamics. Wellness marketing claims outrun validated approved outcomes for DIY research-peptide use.
Safety literacy
GH-axis class questions (edema, glucose handling, theoretical proliferation concerns in susceptible people) belong with a clinician — not a blog monitoring protocol. Hunger/cortisol/prolactin folklore vs older GHRPs is often over-claimed online; treat as unverified for gray-market products. Are peptides safe?.
Regulatory and sport snapshot
- U.S.: Not FDA-approved as Ipamorelin wellness therapy.
- Sport: Growth-hormone secretagogues / GHRPs may be prohibited — check current WADA/GlobalDRO.
- WADA sport status tool.
Why no dosage chart?
“Ipamorelin doses” and stack calculators seek protocols for unapproved agents. Literacy refusal. Unit math only: peptide calculator.
Related compounds and comparisons
- CJC-1295 — GHRH partner in folk stacks (DAC literacy)
- CJC-1295 / Ipamorelin — dual stack page
- Planned: ipamorelin vs sermorelin, ipamorelin vs tesamorelin
- Other GHRPs (GHRP-2, GHRP-6, hexarelin) — future profiles
- MK-677 — oral GHS-R1a small molecule (not Ipamorelin)
Frequently asked questions
What is Ipamorelin?
A selective ghrelin-receptor (GHRP) research peptide that stimulates GH release in research contexts. It is not FDA-approved consumer GH therapy.
Is Ipamorelin the same as CJC-1295?
No. Different receptors: GHS-R1a vs GHRH. Stacks are two agents, not one molecule.
Is the CJC/Ipamorelin stack FDA approved?
No. See CJC-1295 / Ipamorelin.
Ipamorelin vs sermorelin or tesamorelin?
All sit in GH-axis conversation neighborhoods but are different entities with different evidence and regulatory stories. Full comparisons are planned; this page will not crown a “best.”
Why no Ipamorelin dosage?
Unapproved status and YMYL harm reduction.
Is Ipamorelin a SARM?
No. SARMs are a different pharmacology class — see SARMs hierarchy.
Sources
- Primary — pharmacology Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
- Primary — human Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID: 10496658.
- Anti-doping World Anti-Doping Agency. The 2026 Prohibited List. S2 lists growth hormone secretagogues and mimetics, including ipamorelin. Accessed November 10, 2026.
- Internal Peptide Tutorials. CJC-1295; CJC-1295 / Ipamorelin; Disclaimers.
Educational GH-axis literacy only. Not medical advice, not a recommendation to use Ipamorelin, and not a dosing guide. We don’t sell peptides. Full disclaimers.